Insmed Incorporated (NASDAQ:INSM) Shares Bought by Los Angeles Capital Management LLC

Los Angeles Capital Management LLC lifted its position in shares of Insmed Incorporated (NASDAQ:INSM) by 164.8% during the 3rd quarter, Holdings Channel.com reports. The fund owned 10,179 shares of the biopharmaceutical company’s stock after buying an additional 6,335 shares during the period. Los Angeles Capital Management LLC’s holdings in Insmed were worth $743,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also modified their holdings of INSM. V Square Quantitative Management LLC purchased a new stake in Insmed during the third quarter worth $30,000. EntryPoint Capital LLC acquired a new position in shares of Insmed during the 1st quarter worth $33,000. GAMMA Investing LLC boosted its position in shares of Insmed by 71.3% in the 3rd quarter. GAMMA Investing LLC now owns 538 shares of the biopharmaceutical company’s stock worth $39,000 after buying an additional 224 shares in the last quarter. First Horizon Advisors Inc. grew its stake in Insmed by 83.4% in the 2nd quarter. First Horizon Advisors Inc. now owns 631 shares of the biopharmaceutical company’s stock valued at $42,000 after acquiring an additional 287 shares during the last quarter. Finally, Exchange Traded Concepts LLC increased its holdings in Insmed by 522.5% during the 3rd quarter. Exchange Traded Concepts LLC now owns 747 shares of the biopharmaceutical company’s stock valued at $55,000 after acquiring an additional 627 shares in the last quarter.

Insider Transactions at Insmed

In related news, insider Martina M.D. Flammer sold 13,436 shares of Insmed stock in a transaction on Monday, September 16th. The shares were sold at an average price of $74.92, for a total transaction of $1,006,625.12. Following the transaction, the insider now owns 106,134 shares in the company, valued at approximately $7,951,559.28. The trade was a 11.24 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Michael Alexander Smith sold 27,871 shares of the stock in a transaction on Friday, September 13th. The shares were sold at an average price of $74.35, for a total value of $2,072,208.85. Following the completion of the sale, the insider now owns 67,856 shares of the company’s stock, valued at approximately $5,045,093.60. This represents a 29.12 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 78,882 shares of company stock worth $5,765,446 in the last three months. 4.60% of the stock is currently owned by company insiders.

Insmed Stock Performance

Shares of INSM stock opened at $66.29 on Friday. The company has a debt-to-equity ratio of 2.03, a quick ratio of 5.99 and a current ratio of 6.37. The firm has a market capitalization of $11.86 billion, a price-to-earnings ratio of -11.94 and a beta of 1.12. Insmed Incorporated has a one year low of $21.92 and a one year high of $80.53. The company has a 50 day moving average price of $72.23 and a 200 day moving average price of $64.13.

Insmed (NASDAQ:INSM) last released its quarterly earnings data on Thursday, October 31st. The biopharmaceutical company reported ($1.27) EPS for the quarter, missing analysts’ consensus estimates of ($1.19) by ($0.08). The firm had revenue of $93.40 million during the quarter, compared to analyst estimates of $93.36 million. During the same period last year, the firm posted ($1.10) EPS. The firm’s revenue was up 18.1% on a year-over-year basis. Sell-side analysts anticipate that Insmed Incorporated will post -5.42 EPS for the current year.

Wall Street Analyst Weigh In

Several analysts have issued reports on the stock. Bank of America upped their price target on shares of Insmed from $84.00 to $86.00 and gave the company a “buy” rating in a report on Wednesday, October 9th. HC Wainwright reissued a “buy” rating and set a $90.00 price target on shares of Insmed in a research report on Friday, November 1st. UBS Group boosted their price target on Insmed from $78.00 to $84.00 and gave the stock a “buy” rating in a report on Friday, August 9th. Stifel Nicolaus increased their price objective on Insmed from $74.00 to $88.00 and gave the company a “buy” rating in a research note on Friday, August 9th. Finally, StockNews.com downgraded shares of Insmed from a “hold” rating to a “sell” rating in a research note on Friday, August 9th. One analyst has rated the stock with a sell rating and sixteen have issued a buy rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $83.07.

About Insmed

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.